Vigabatrin--plasma enantiomer concentrations and clinical effects.
Plasma concentrations of the [R]- and [S]- enantiomers of the new anticonvulsant vigabatrin were measured by an enantiospecific gas-liquid chromatographic assay in a group of therapy-resistant epileptic patients in whom racemic vigabatrin was added to their existing antiepileptic drug regimens. The peak plasma concentrations of the biologically active [S]-enantiomer of vigabatrin were correlated with those of the [R]-enantiomer, with drug dose, seizure frequency and change in score on various tests of psychological function administered prior to and when the subjects were under steady-state conditions following vigabatrin therapy. Plasma [S]-vigabatrin concentrations correlated with drug dose, [R]-vigabatrin concentration and change in score of certain psychological tests reflecting verbal memory, recall and speed of information processing. No definite pharmacokinetic interactions were detected, though plasma phenobarbitone concentrations tended to fall during vigabatrin administration. There were too few data to assess the relation between [S]-vigabatrin concentrations and seizure frequency.
Sheean
G
G
Department of Neurology, Royal Brisbane Hospital.
Schramm
T
T
Anderson
D S
DS
Eadie
M J
MJ
D000293:Adolescent; D000328:Adult; D000614:Aminocaproates / Q000097:blood* / Q000627:therapeutic use; D000927:Anticonvulsants / Q000097:blood / Q000627:therapeutic use; D004828:Epilepsies, Partial / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D017029:Epilepsy, Complex Partial / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006706:Homeostasis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D009994:Osmolar Concentration; D013237:Stereoisomerism; D020888:Vigabatrin
D000614:Aminocaproates; D000927:Anticonvulsants; D020888:Vigabatrin